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ScienceDirectConnective tissue calcifying diseases (CTCs) are characterized
by abnormal calcium deposition in connective tissues. CTCs
are caused by multiple factors including chronic diseases (Type
II diabetes mellitus, chronic kidney disease), the use of
pharmaceuticals (e.g. warfarin, glucocorticoids) and inherited
rare genetic diseases such as pseudoxanthoma elasticum
(PXE), generalized arterial calcification in infancy (GACI) and
Keutel syndrome (KTLS). This review explores our current
knowledge of these rare inherited CTCs, and highlights the
most promising avenues for pharmaceutical intervention.
Advancing our understanding of rare inherited forms of CTC is
not only essential for the development of therapeutic strategies
for patients suffering from these diseases, but also fundamental
to delineating the mechanisms underpinning acquired chronic
forms of CTC.
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Introduction
A disease or disorder is defined as rare in Europe when it
affects less than 1 in 2000 people. In the EU, as many as
30 million people alone may be affected by one of over
6000 existing rare diseases (http://www.eurordis.org/
about-rare-diseases). A number of rare inherited forms ofCurrent Opinion in Pharmacology 2016, 28:14–23 Connective Tissue Calcifying diseases (CTCs) have been
identified, and are characterized by abnormal calcium
mineral deposition in connective tissues. Although all
tissue has the potential to undergo calcification, several
tissues have a higher propensity to calcify including skin,
kidney, blood vessels and cardiac valves [1]. There are
multiple mechanisms by which connective tissue calcifica-
tion can progress, however these mechanisms are not
exclusive and multiple pathologies can concurrently pro-
mote aberrant calcification. Common causes of connective
tissue calcification include aging, as well as diseases such as
atherosclerosis, chronic kidney disease (CKD) and Type II
diabetes mellitus. Connective tissue calcification is also the
result of specific rare congenital diseases such as general-
ized arterial calcification of infancy (GACI), pseudox-
anthoma elasticum (PXE), Hutchinson–Gilford progeria
syndrome (HGPS), arterial calcification due to deficiency
of CD73 (ACDC) and Keutel syndrome (KTLS) [2].
Despite scarcity of cases, these diseases provide significant
insight into the complex biological processes underpinning
connective tissue calcification. The single gene deficien-
cies of rare inherited forms of CTC have allowed the
identification of specific targets and the development of
novel animal models to further study the process of con-
nective tissue calcification. Furthermore, data from
patients and animal models has resulted in the elucidation
of pathways involved in both the promotion and inhibition
of connective tissue calcification.
Basic mechanisms of bone mineralization
In order to understand more fully the mechanisms under-
pinning connective tissue calcification, it is important to
appreciate the physiological process of bone mineraliza-
tion, which occurs through the deposition of hydroxyapa-
tite (HA) onto a collagenous extracellular matrix (ECM).
HA crystal formation is regulated by matrix vesicles (MVs),
which maintain calcium (Ca2+) and inorganic phosphate
(Pi) concentrations at levels optimal for HA nucleation. As
the HA crystals grow they disrupt the MV and deposit onto
the ECM where they continue to grow [3]. The transport of
Ca2+ into MVs is primarily controlled by annexin channels,
whereas Pi is transported into the MV by the type III
sodium-dependent Pi co-transporter-1 (PiT-1) [4]. Intra-
cellular to extracellular channelling of pyrophosphate (PPi)
is mediated by ANK [5].
Whilst Pi acts to promote HA crystal formation, PPi,
generated by ecto-nucleotide pyrophosphatase/phospho-
diesterase 1 (ENPP1), has a dual role as an inhibitor of HAwww.sciencedirect.com
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PPi is controlled by a complex interaction between the
regulatory phosphatases tissue non-specific alkaline phos-
phatase (TNAP) and phosphoethanolamine/phosphocho-
line phosphatase (PHOSPHO1). TNAP hydrolyses PPi in
the ECM to release Pi and PHOSPHO1 hydrolyses
phosphocholine and phosphoethanolamine to produce
Pi inside the MVs. Together these phosphatases control
the Pi/PPi balance during the mineralization process [7].
Further feedback signalling allows modulation of miner-
alization; inorganic pyrophosphatase stimulates minerali-
zation without reducing PPi levels [8]. Both exogenous Pi
and PPi upregulate the bone sialoprotein osteopontin
(OPN), which in turn inhibits mineralization through
restricting HA crystal formation and growth [9]. Intrigu-
ingly, a clear dissociation in the hierarchical roles of PPi
and OPN has recently been highlighted [10].
Overview of mechanisms of connective tissue
calcification
The control and regulation of connective tissue calcifica-
tion is a multifactorial process which shares many similari-
ties with that of the physiological matrix mineralization
during skeletal development described previously. A
wealth of knowledge emanates from research into vascular
calcification, a strong and independent predictor of mor-
bidity and mortality in cardiovascular disease [2]. Indeed
normal vascular smooth muscle cell (VSMC) populations
contain cells that undergo phenotypic transition to osteo-
cytic, osteoblastic and chondrocytic cells in a calcified
environment [11]. In VSMCs, MVs have been shown to
nucleate hydroxyapatite crystals that contain calcium and
inorganic phosphate [12] forming the first nidus for
calcification. This nucleation occurs via a tightly controlledTable 1
The cause and phenotype of significant rare inherited CTCs
CTC disease 
Pseudoxanthoma elasticum (PXE) ABCC6 deficie
Generalized arterial calcification in infancy (GACI) ENPP1 deficie
Arterial calcification due to deficiency of CD73 (ACDC) CD73 deficienc
Hutchinson–Gilford progeria syndrome (HGPS) Progerin (lamin
Keutel syndrome (KTLS) MGP deficienc
Fibrodysplasia ossificans progressiva (FOP) ACVR1 gain of
Coeliac disease with epilepsy and cerebral
calcifications (CEC)
Unknown 
Idiopathic basal ganglia calcification (IBGC) PiT-2 and/or P
www.sciencedirect.com balance of inhibitors and inducers comparable to that seen
in bone, with PHOSPHO1, sphingomyelinase 3 (SMPD3),
TNAP, annexins, ANK and ENPP1 playing key regulatory
roles [2,12]. Furthermore, MVs derived from VSMCs
have been shown to contain negative regulators of hydroxy-
apatite crystal nucleation and growth, such as fetuin-A and
matrix gla protein (MGP) [13]. In cooperation with local
mediators such as PPi [6], these molecules protect the
arteries from mineral deposition and growth. In the ab-
sence of these inhibitors, or following the stimulation of
apoptotic processes [14], together with the osteogenic
activity of VSMCs, vascular calcification readily proceeds.
A key role for pyrophosphate (PPi) in rare
CTCs
It has recently been established that connective tissue
calcification is contingent on circulating PPi levels rather
than local PPi production [15]. As previously highlighted,
PPi not only acts as a potent inhibitor of connective tissue
calcification, but also contributes directly to the calcifica-
tion process. Intriguingly, one of the identified sources of
systemic PPi is through ATP binding cassette sub-family
C member 6 (ABCC6)-mediated ATP release from hepa-
tocytes [16]. Still within the vasculature of the liver,
released ATP is rapidly converted to PPi and AMP by
ENPP1, which are in turn distributed throughout the
body via the circulation. In connective tissues the metab-
olite AMP is further hydrolysed into Pi and adenosine by
ecto-50-nucleotidase (CD73). Adenosine in turn inhibits
TNAP transcription, thus decreasing Pi production and
more importantly maintaining PPi levels [17]. Different
perturbations in this mechanism can contribute to several
rare CTCs (Table 1) which whilst varying in degree of
severity and phenotype, show notable overlap.Cause Phenotype
ncy Elastic fibre mineralization in skin, eyes, and
arteries.
ncy Widespread mineralization of arteries, and to
a lesser extent joints.
y Mineralization of arteries and joints in the
extremities.
 A mutant) Premature aging, atherosclerosis and
calcification of blood vessels and the aortic
valve.
y Facial abnormalities, calcification of the
larynx trachea and bronchi, along with
auricular, nasal and rib cartilage.
 function Progressive heterotopic endochondral
ossification of skeletal muscle, fascia,
tendons, and ligaments.
Occipital epilepsy, with bilateral occipital
calcifications and coeliac disease.
DGFR-B deficiency? Calcification of the basal ganglia as well as
the thalamus and cerebellum.
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calcification
Pseudoxanthoma elasticum (PXE)
A defect in the ABCC6 gene is responsible for pseudox-
anthoma elasticum (PXE) (#OMIM 264800), an inherited
autosomal recessive multisystem disorder affecting con-
nective tissues in humans. The ABCC6 gene carried by
chromosome 16p13.11 encodes a trans-membrane ATP-
binding cassette transporter, subfamily C, member 6 [15],
which is primarily expressed in the hepatocyte and to a
lesser extent in the proximal tubule cells in the kidney.
The phenotypic expression of the disease is characterized
by the fragmentation and mineralization of elastic fibres
in the skin, retina and arterial wall [16–18]. The symp-
toms are represented by unaesthetic skin folds, central
blindness and adverse cardiovascular events (Figure 1).
To date, the role of ABCC6 and the nature of its sub-
strate(s) in the PXE disease remain unknown and are
presently subject to extensive research efforts worldwide.
After several inconclusive hypotheses, recent seminal
studies disclosed that ABCC6 participates in the release
of intracellular nucleotides (such as ATP) by a yet un-
known pathway in the liver [19]. This results in a
decrease in the extracellular ATP available for degrada-
tion by hepatic ecto-nucleotidase enzymes (such as
ENPP1), which ultimately leads to less circulating PPi,
a powerful tissue and circulating anti-calcifying factor (as
highlighted above) [20]. This important study places the
liver, and to a lesser extent the kidney, as the metabolicFigure 1
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Diffuse arterial calcifications visualized by CT-scan in the lower limb
arteries of a patient with pseudoxanthoma elasticum (PXE).
Current Opinion in Pharmacology 2016, 28:14–23 control centre of PXE associated calcification, with almost
40% of the overall systemic PPi production generated
from the liver [21], which cannot be compensated for by
the local release of PPi through alternative ectonucleoti-
dic pathways (i.e. ENPP1 or TNAP).
Additional confounding factors of genetic [22] and/or met-
abolic origin [23–25] highlight the complex direct and
remote interactions in PXE. Further clinical manifesta-
tions of PXE, such as elevated thrombotic susceptibility,
increased myogenic tone and vascular malformations
[26,27] may be a result of altered purinergic signalling,
which unequivocally mediates complex autocrine and
paracrine cellular signalling pathways within various
tissues [28–31].
PXE represents a prototypic metabolic disease that shares
some of the features of calcifying vascular diseases of
acquired metabolic origin such as type II diabetes melli-
tus and CKD [2]. The discovery of the role of ABCC6
raises new challenging questions on the central role of the
hepato-renal axis in the connective-tissue calcifying pro-
cess. From a clinical point of view, the current absence of
an efficient targeted therapy requires the tight control and
management of the typical cardiovascular risk factors
associated with PXE, in addition to the limitation of
pro-calcifying conditions. Promising new perspectives
for etiologic treatments are however in progress, and
may shortly yield exciting new treatment options for
patients with PXE.
Generalized arterial calcification in infancy (GACI)
Mutations in ENPP1 are known to cause a rare human
disease phenotype, namely generalized arterial calcifica-
tion in infancy (GACI, MIM# 208000), formerly known as
idiopathic infantile arterial calcification (IIAC) [32]. In
GACI, calcification of the media of large and medium-
sized arteries (Figure 2a) is associated with intimal pro-
liferation (Figure 2b) leading to arterial stenosis. Depend-
ing on the severity and the local distribution of the calcific
stenoses, affected infants can present with neonatal heart
failure, arterial hypertension and death within the first six
months of life [33]. To date, more than 40 different
causative mutations in ENPP1 have been identified in
GACI patients accounting for approximately 70% of the
affected cases [33]. Based on the number of reported
pathogenic variants in NHLBI ESP6500 (16 carriers in
6021 individuals) a carrier frequency of one in 376 indi-
viduals (0.27%), and a disease frequency of one in 566,000
individuals can be estimated [34].
The cardiovascular phenotype of the disease is quite
variable [35] and can even vary to a great extent between
siblings carrying the same mutations: of two Taiwanese
siblings with identical genotype, one developed exten-
sive arterial calcification and severe hypertension, and
died of heart failure at the age of 6 weeks, while the otherwww.sciencedirect.com
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Figure 2
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(a) (b)
(a) Sonography of the femoral artery (Fem Art, arrows) of an infant with Generalized Arterial Calcification of Infancy (GACI). Note the increased
echogenicity of the arterial wall. (b) Histology section of the aorta from an infant who died from GACI. Note the deposition of crystallized material
(arrows) at the level of the lamina elastica interna and myointimal proliferation (H&E staining).sibling had an uncomplicated clinical course [36]. The
phenotype of the disease is recapitulated in the so-called
tiptoe-walking (ttw/ttw) mouse associated with articular
cartilage and peri-spinal ligament calcification and also
with aortic calcification [37,38]. In these mice, connective
tissue calcification progresses to hyperostotic joints and
spine ankylosis leading to the ‘tiptoe-walking’ pheno-
type. A comparable phenotype can be found in asj/asj
mice, which carry the V246D missense mutation [39,40]
and in Enpp1 knockout mice [41,42,43]. Intriguingly,
deficiency of ENPP1 has also been shown to exert pro-
tective effects against obesity and diabetes in mice [44],
however, the metabolic phenotype has yet to be assessed
in GACI patients, and warrants future investigation.
Hypophosphataemia can compensate for the GACI phe-
notype and this might reflect a physiologic compensation
mechanism rather than a primary defect [33]. However,
several mutations in the ENPP1 gene can result in the
phenotype of autosomal-recessive hypophosphatemic
rickets (ARHR) without any arterial calcification
[45,46], suggesting a different pathway involved in the
generation of ARHR linked to direct renal Pi-handling
functions of ENPP1. Treatment with synthetic analogues
of pyrophosphate, namely bisphosphonates seems to sig-
nificantly increase survival in patients with GACI [33],
however, spontaneous regression of the calcifications can
occur [47], and studies on the exact long term natural
history of the disease are pending. Based on the finding
that mutations in ENPP1 can also cause PXE and that
mutations in ABCC6 can also cause GACI it has become
obvious that an overlap of genotype and phenotype inwww.sciencedirect.com GACI and PXE exists [48]. This has led to the hypothesis
of a shared pathogenic principle in GACI and PXE [49],
which finally held to be true. Most recently, subcutaneous
administration of an ENPP1-Fc fusion protein was shown
to prevent the mortality, vascular calcifications and se-
quelae of disease in the asj/asj mouse model of GACI
[50]. This very promising preclinical study may pave
the way to clinical trials with enzyme replacement thera-
py in patients with this rare disorder carrying mutations in
ENPP1.
Arterial calcification due to deficiency of CD73 (ACDC)
Calcification of joints and arteries (arterial calcification
due to deficiency of CD73 (ACDC); OMIM# 211800), as
originally described by Magnus-Levy [51] was recently
shown to be caused by deficiency of CD73, encoded by
the NT5E gene [52,53]. Clinical features include calci-
fied large vessels and periarticular calcifications in the
joints of the hands and feet. CD73 has 50 exonucleotidase
activity that converts AMP to adenosine and Pi [54].
Receptor binding of adenosine triggers a downstream
intracellular signalling cascade that results in inhibition
of TNAP activity [55]. Thus, it has been proposed that
increased TNAP activity is central to the mechanism
underpinning ACDC.
Hutchinson–Gilford progeria syndrome
The rare premature aging disorder Hutchinson–Gilford
progeria syndrome (HGPS) is characterized by excessive
atherosclerosis and both blood vessel and aortic valve
calcification [56–58]. HGPS patients express progerin, a
mutant form of lamin A. Progerin expression results inCurrent Opinion in Pharmacology 2016, 28:14–23
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mal higher-order chromatin organization [59,60]. Knock-
in mice expressing progerin exhibit reduced circulating
PPi levels similar to mice lacking ENPP1 [61]. Interest-
ingly this low PPi is the result of increased TNAP activity
and decreased extracellular ATP due to mitochondrial
dysfunction. Consistent with this observation of
supressed PPi levels, these mice show excessive aortic
calcification which is ameliorated by exogenous PPi ad-
ministration [61]. These findings suggest connective tis-
sue calcification in HGPS shares key features of PXE
(decreased ATP), GACI (low PPi) and ACDC (increased
TNAP activity), further demonstrating the overlap be-
tween these CTCs.
Keutel syndrome
Keutel syndrome (KTLS) (OM#245150) is an extremely
rare autosomal recessive disorder that manifests during
the early childhood of patients predominantly from the
Middle East. Since its first description in 1971 by Keutel
and colleagues in two consanguineous siblings [62], less
than 30 patients have been reported to date.
Foremost clinical characteristics of KTLS include abnor-
mal calcification in laryngal, tracheobronchial, auricular,
nasal and rib cartilage, brachytelephalangism and facial
abnormalities such as mid-facial hypoplasia, depressed
nasal bridge and reduced alae nasi [62–67]. Further
symptoms include mild to severe unilateral or bilateral
hearing loss, multiple peripheral pulmonary artery steno-
sis, mental retardation and respiratory conditions, includ-
ing dyspnoea and cough, that lead to hospitalization and
incidentally to diagnosis [62–68]. Additionally, long-term
follow-up studies have revealed that, KTLS patients
develop skin lesions, typically after 30 years of age [69]
and suffer chronic and progressive respiratory disease
caused by gradual laryngotrachebronchial calcification
and stenosis [65,69]. Subsequent post-mortem examina-
tion of the youngest sibling originally described has also
uncovered calcification of pulmonary, coronary, hepatic,
renal, meningeal and cerebral arteries [65–68].
It is well established that KTLS is due to loss-of-function
mutations in the MGP gene [66,67,70–72], encoding
MGP, a potent local mineralization inhibitor predomi-
nantly expressed by chondrocytes and VSMCs [73]. Post-
translational modifications of MGP, such as vitamin K-
dependent glutamate carboxylation and serine phosphor-
ylation, have been shown to trigger these inhibitory
properties [74]. Mice lacking Mgp develop abnormal
cartilage calcification and extensive vascular calcification
that leads to premature death due to aortic dissection [73].
Although all of the seven mutations reported in humans
predict absent or non-functional MGP, they result in
variable phenotypes with cardinal and secondary features
of variable penetrance [66,67,70–72]. Moreover, in con-
trast to Mgp-deficient mice, with the exception of oneCurrent Opinion in Pharmacology 2016, 28:14–23 clinical case [65,67], vascular calcification has not been
observed in KTLS patients. Interestingly, measurements
of circulating MGP species have highlighted high levels
of phosphorylated MGP [67]. This suggests that phos-
phorylation-dependent residual MGP activity may con-
tribute to the absence of arterial calcification and more
generally, that the variable phenotypic features observed
clinically in KTLS could be explained by altered levels of
the different MGP species.
Systemic hypertension is frequently found in KTLS
patients before adulthood. Therefore, under the control
of standard anti-hypertensive medication [69], KTLS has
a good prognosis. Nevertheless, life expectancy of
patients primarily depends on the severity of the associ-
ated respiratory complications. Indeed, symptomatic
treatment with corticosteroids or bronchodilators is not
always effective [65,67,69]. Interestingly, a recent study
reported the efficacy of BMP inhibitors in reducing
vascular calcification and improving survival in Mgp/
mice [75]. Besides targeting vascular calcification,
which is very rare in KTLS, BMP inhibition strategies
could also be employed as a pharmaceutical approach to
reduce abnormal cartilage calcification. This would have
particularly high therapeutic value if successfully devel-
oped to treat tracheobronchial tree calcification, which
initiates respiratory distress and complications, and ulti-
mately determines the quality and duration of life of
KTLS patients.
Fibrodysplasia ossificans progressiva (FOP)
Fibrodysplasia ossificans progressiva (FOP; OMIM#
135100) is a devastating rare disease, characterized by
the progressive heterotopic endochondral ossification
(HOE) of skeletal muscle, fascia, tendons, and ligaments
[76]. The range of joint motion in FOP patients becomes
gradually and progressively limited by HOE. Indeed,
this ossification is so diffuse that it is commonly referred
to as a second skeleton [76]. HOE occurs in flare ups and
is most commonly triggered by muscle injury, as also
observed in Abcc6/ mice [77], and viral infection. Un-
like other CTCs discussed in this review, FOP is not the
result of a deficiency but rather a gain of function muta-
tion. All patients with the typical FOP phenotype have a
substitution of the Arg206 residue for a His residue in
Activin A receptor type I (ACVR1) which is a type 1 Bone
Morphogenetic Protein Receptor (BMPR) [78]. This
A206H ACVR1 exhibits ligand free activation of its
BMP signalling pathways and a greatly enhanced re-
sponse to BMP [79,80]. Studies suggest that FKBP1A
(a protein that negatively regulates BMP type I R) has
reduced binding capabilities to A206H ACVR1, prevent-
ing it from modulating its activity [79–81]. Knock-in mice
that express the A206H ACVR1 recapitulate the pheno-
type of FOP patients [82], with data from these mice and
other models suggesting that Tie2+ mesenchymal cells
are the progenitors of the HOE through their response towww.sciencedirect.com
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FOP symptoms is limited to glucocorticoids and non-
steroidal anti-inflammatories to minimize flare ups and
pain [76], with no therapeutic strategy currently available
to inhibit or prevent the HOE associated with this rare
CTC. Given the positive effects of BMP inhibitors in
Mgp-deficient mice, it would be beneficial to recapitulate
these studies in the FOP mouse model as a first step to a
pharmaceutical approach.
Rare CTCs of the brain
There are a number of disorders demonstrating con-
nective tissue calcification in the brain, including coe-
liac disease with Epilepsy and Cerebral calcifications
(CEC; OMIM# 226810). To date, less than 200 CECFigure 3
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due to mitochondrial dysfunction, combined these effects of progerin result
www.sciencedirect.com patients have been reported in the literature [86]. The
suspected Mendelian basis of this disease is character-
ized by three primary pathologies. The first is epilepsy,
most commonly occipital epilepsy. Drug resistance is
also common for this epilepsy with evolution towards
epileptic encephalopathy. The second pathology is
cerebral calcification, with bilateral occipital calcifica-
tions most frequently observed. The third pathology is
coeliac disease, although in older patients (>2 years)
bowel symptoms are less common [87,88]. Whilst folate
deficiency has been proposed as the cause of CEC [89],
recent studies suggest a possible autoimmune compo-
nent to the disease with the identification of autoanti-
bodies to transglutaminase isoenzyme 6 in the serum of
a CEC patient [90]. Current CEC treatment regimensmitochondrial
dysfunction
TNAP
denosine
OPN
BMPs
MGP
(KTLS )
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(FOP )
ydroxyapatite
PiPPi
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eposition. A206H ACVR1 exhibits an enhanced response to BMP
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the efficacy of which has been shown to directly
correlate with how early treatment is implemented
[87,88].
Idiopathic Basal Ganglia Calcification (IBGC; OMIM#
213600) is characterized by calcification of the basal
ganglia as well as the thalamus and cerebellum [91].
Patients display a range of neuropsychiatric and move-
ment disorders including dementia, psychosis, Parkinson-
ism, dystonia, and migraine. Mutations in the gene for
type III sodium-dependent Pi co-transporter 2 (PiT-2)
leading to impaired or loss of function have been identi-
fied in several patient cohorts [92–96]. Direct evidence for
a role for PiT-2 in IBGC was first provided by studies
investigating the phenotype of mice lacking PiT-2.
These mice develop calcification predominantly in the
thalamus but also in the basal ganglia and brain cortex
[97]. Of particular interest, histological analyses of these
mice suggest that calcification initiates in or around the
vasculature which closely mimics the phenotype ob-
served in IBGC patients [91]. Mutations in the gene
for platelet derived growth factor receptor B (PDGFRB)
have also been described in IBGC patients [98].
PDFGRB regulates PiT-1 in VSMCs [99,100] and a role
for this molecule in IBGC would be consistent with a
vascular origin of the calcification. Considering IBGC
patients have normal circulating Pi levels [91] any role
Pit-2 and/or PDGFRB may play in calcification would be
local to the affected tissue. This highlights the heteroge-
neity of Pi regulation in different tissues which should be
an important consideration when planning pharmaceuti-
cal interventions for CTCs.
Future directions
Much of our understanding of the potential mechanisms
underpinning CTCs (Figure 3) has arisen through the use
of rodent models. However, significant differences be-
tween physiology, anatomy, and pathology exist between
mice and men. In contrast, large animal models can show
markedly greater similarity to humans [101]. The recent
explosion of precise and efficient genome editing tech-
niques through CRISPR/Cas9 technology permits the
generation of tailored models for translational research
[102]. These novel systems provide huge potential for
large animal models for future investigations into the
regulatory factors and molecular pathways that contribute
to rare inherited forms of CTC in vivo.
At present, only very limited pharmaceutical strategies
exist to inhibit connective tissue calcification. Further
pre-clinical and clinical studies are required to examine
new approaches such as targeting mechanisms common to
different CTCs (e.g. PPi regulation) and/or enzyme re-
placement therapy (e.g. ENPP1). These investigations
may bring to fruition the first comprehensive treatment
for both inherited and acquired CTCs.Current Opinion in Pharmacology 2016, 28:14–23 Conflict of interest statement
Nothing declared.
Acknowledgements
This work was supported by an Institute Strategic Programme Grant (BB/
J004316/1) from the Biotechnology and Biological Sciences Research
Council (BBSRC) (VEM, NAR), the French Society of Vascular Medicine
(GL), the PXE-France french patients’ association (GL), PXE-International
(GL), Universite´ de Lorraine (HK), Centre National de la Recherche
Scientifique (CNRS) (HK), Institut National de la Sante´ et de la Recherche
Me´dicale (INSERM) (HK) and Deutsche Forschungsgemeinschaft (DFG)
(FR) and The Hungarian Scientific Research Fund (OTKA) (AV).
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Anderson HC, Morris DC: Mineralization. Physiology and
Pharmacology of Bone. Handbook of Experimental
Pharmacology. Berlin Heidelberg: Springer; 1993, 267-298.
2. Zhu D, Mackenzie NCW, Farquharson C, Macrae VE:
Mechanisms and clinical consequences of vascular
calcification. Front Endocrinol 2012, 3.
3. Anderson HC: Matrix vesicles and calcification. Curr Rheumatol
Rep 2003, 5:222-226.
4. Wuthier RE, Lipscomb GF: Matrix vesicles: structure,
composition, formation and function in calcification. Front
Biosci 2011, 16:2812-2902.
5. Ho AM, Johnson MD, Kingsley DM: Role of the mouse ank gene
in control of tissue calcification and arthritis. Science 2000,
289:265-270.
6. Mackenzie NCW, Huesa C, Rutsch F, MacRae VE: New insights
into NPP1 function: lessons from clinical and animal studies.
Bone 2012, 51:961-968.
7. Yadav MC, Sima˜o AMS, Narisawa S, Huesa C, McKee MD,
Farquharson C, Milla´n JL: Loss of skeletal mineralization by the
simultaneous ablation of PHOSPHO1 and alkaline
phosphatase function: a unified model of the mechanisms of
initiation of skeletal calcification. J Bone Miner Res 2011,
26:286-297.
8. Polewski MD, Johnson KA, Foster M, Milla´n JL, Terkeltaub R:
Inorganic pyrophosphatase induces type I collagen in
osteoblasts. Bone 2010, 46:81.
9. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R,
Milla´n JL: Concerted regulation of inorganic pyrophosphate
and osteopontin by Akp2, Enpp1, and Ank: an integrated
model of the pathogenesis of mineralization disorders. Am J
Pathol 2004, 164:1199-1209.
10.

Yadav MC, Huesa C, Narisawa S, Hoylaerts MF, Moreau A,
Farquharson C, Milla´n JL: Ablation of osteopontin improves the
skeletal phenotype of Phospho1S/S mice. J Bone Miner Res
2014, 29:2369-2381.
This study demonstrates that osteopontin (Opn) is elevated in Phospho1
knock out mice and that concurrent knockout of Opn with Phospho1
rescues the skeletal phenotype.
11. Zhu D, Mackenzie NCW, Milla´n JL, Farquharson C, MacRae VE:
The appearance and modulation of osteocyte marker
expression during calcification of vascular smooth muscle
cells. PLoS One 2011, 6:e19595.
12.

Kapustin AN, Chatrou MLL, Drozdov I, Zheng Y, Davidson SM,
Soong D, Furmanik M, Sanchis P, De Rosales RTM, Alvarez-
Hernandez D et al.: Vascular smooth muscle cell calcification is
mediated by regulated exosome secretion. Circ Res 2015,
116:1312-1323.
This study identifies matrix vesicles as exosomes and demonstrates that
factors that can increase exosome release promote vascular calcifica-
tion.www.sciencedirect.com
Rare connective tissue calcifying diseases Rashdan et al. 2113.

Cui L, Houston DA, Farquharson C, MacRae VE: Characterisation
of matrix vesicles in skeletal and soft tissue calcification. Bone
2016. in press.
This study identifies matrix vesicles as exosomes and demonstrates that
factors that can increase exosome release promote vascular calcifica-
tion.
14.

Dai XY, Zhao MM, Cai Y, Guan QC, Zhao Y, Guan Y, Kong W,
Zhu WG, Xu MJ, Wang X: Phosphate-induced autophagy
counteracts vascular calcification by reducing matrix vesicle
release. Kidney Int 2013, 83:1042-1051.
This paper demonstrates that autophagy is dependent on oxidative stress
and that inhibiting it increases calcification, whilst inducing autophagy
decreases calcification.
15. Le Saux O, Urban Z, Tschuch C, Csiszar K, Bacchelli B,
Quaglino D, Pasquali-Ronchetti I, Pope FM, Richards A, Terry S
et al.: Mutations in a gene encoding an ABC transporter cause
pseudoxanthoma elasticum. Nat Genet 2000, 25:223-227.
16. Hu X, Plomp AS, van Soest S, Wijnholds J, de Jong PT, Bergen AA:
Pseudoxanthoma elasticum: a clinical, histopathological, and
molecular update. Surv Ophthalmol 2003, 48:424-438.
17. Uitto J, Bercovitch L, Terry SF, Terry PF: Pseudoxanthoma
elasticum: progress in diagnostics and research towards
treatment: summary of the 2010 PXE International Research
Meeting. Am J Med Genet A 2011, 155:1517-1526.
18. Neldner KH: Pseudoxanthoma elasticum. Clin Dermatol 1988,
6:1-159.
19.

Jansen RS, Kucukosmanoglu A, de Haas M, Sapthu S, Otero JA,
Hegman IE, Bergen AA, Gorgels TG, Borst P, van de Wetering K:
ABCC6 prevents ectopic mineralization seen in
pseudoxanthoma elasticum by inducing cellular nucleotide
release. Proc Natl Acad Sci U S A 2013, 110:20206-20211.
This study reveals that the factor that normally prevents PXE is pyropho-
sphate, which is provided to the circulation in the form of nucleoside
triphosphates.
20. Terkeltaub RA: Inorganic pyrophosphate generation and
disposition in pathophysiology. Am J Physiol Cell Physiol 2001,
281:C1-C11.
21.

Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Varadi A,
Plomp A, Bergen AA, Oude Elferink RP, Borst P et al.: ABCC6-
mediated ATP secretion by the liver is the main source of the
mineralization inhibitor inorganic pyrophosphate in the
systemic circulation-brief report. Arterioscler Thromb Vasc Biol
2014, 34:1985-1989.
This is the first report to demonstrate that the liver is the main source of
circulating ATP and that this is mediated by ABCC6.
22. Hosen MJ, Van Nieuwerburgh F, Steyaert W, Deforce D, Martin L,
Leftheriotis G, De Paepe A, Coucke PJ, Vanakker OM: Efficiency of
exome sequencing for the molecular diagnosis of
pseudoxanthoma elasticum. J Invest Dermatol 2015, 135:992-998.
23. Kuzaj P, Kuhn J, Michalek RD, Karoly ED, Faust I, Dabisch-
Ruthe M, Knabbe C, Hendig D: Large-scaled metabolic profiling
of human dermal fibroblasts derived from pseudoxanthoma
elasticum patients and healthy controls. PLoS One 2014,
9:e108336.
24. Boraldi F, Bartolomeo A, Li Q, Uitto J, Quaglino D: Changes in
dermal fibroblasts from Abcc6(-/-) mice are present before
and after the onset of ectopic tissue mineralization. J Invest
Dermatol 2014, 134:1855-1861.
25. Boraldi F, Annovi G, Guerra D, Paolinelli Devincenzi C, Garcia-
Fernandez MI, Panico F, De Santis G, Tiozzo R, Ronchetti I,
Quaglino D: Fibroblast protein profile analysis highlights the
role of oxidative stress and vitamin K recycling in the
pathogenesis of pseudoxanthoma elasticum. Proteomics Clin
Appl 2009, 3:1084-1098.
26. Kauffenstein G, Pizard A, Le Corre Y, Vessieres E, Grimaud L,
Toutain B, Labat C, Mauras Y, Gorgels TG, Bergen AA et al.:
Disseminated arterial calcification and enhanced myogenic
response are associated with abcc6 deficiency in a mouse
model of pseudoxanthoma elasticum. Arterioscler Thromb Vasc
Biol 2014, 34:1045-1056.
27. Vasseur M, Carsin-Nicol B, Ebran JM, Willoteaux S, Martin L,
Leftheriotis G, Angers PXECCg: Carotid rete mirabile andwww.sciencedirect.com pseudoxanthoma elasticum: an accidental association? Eur J
Vasc Endovasc Surg 2011, 42:292-294.
28. Burnstock G, Vaughn B, Robson SC: Purinergic signalling in the
liver in health and disease. Purinergic Signal 2014, 10:51-70.
29. Burnstock G, Evans LC, Bailey MA: Purinergic signalling in the
kidney in health and disease. Purinergic Signal 2014, 10:71-101.
30. Burnstock G, Ralevic V: Purinergic signaling and blood vessels
in health and disease. Pharmacol Rev 2014, 66:102-192.
31. Orriss IR: The role of purinergic signalling in the
musculoskeletal system. Auton Neurosci 2015, 191:124-134.
32. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Hohne W,
Schauer G, Lehmann M, Roscioli T, Schnabel D et al.: Mutations
in ENPP1 are associated with ‘idiopathic’ infantile arterial
calcification. Nat Genet 2003, 34:379-381.
33. Rutsch F, Boyer P, Nitschke Y, Ruf N, Lorenz-Depierieux B,
Wittkampf T, Weissen-Plenz G, Fischer RJ, Mughal Z, Gregory JW
et al.: Hypophosphatemia, hyperphosphaturia, and
bisphosphonate treatment are associated with survival
beyond infancy in generalized arterial calcification of infancy.
Circ Cardiovasc Genet 2008, 1:133-140.
34.

Ferreira C, Ziegler S, Gahl W: Generalized arterial calcification
of infancy. In GeneReviews(R). Edited by Pagon RA, Adam MP,
Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong
CT, Mefford HC, Smith RJ.. Seattle: University of Washington;
2014.
This paper describes the clinical manifestations and epidemiology of
GACI.
35. Dlamini N, Splitt M, Durkan A, Siddiqui A, Padayachee S,
Hobbins S, Rutsch F, Wraige E: Generalized arterial calcification
of infancy: phenotypic spectrum among three siblings
including one case without obvious arterial calcifications. Am
J Med Genet A 2009, 149A:456-460.
36. Cheng KS, Chen MR, Ruf N, Lin SP, Rutsch F: Generalized
arterial calcification of infancy: different clinical courses in
two affected siblings. Am J Med Genet A 2005, 136:210-213.
37. Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S:
Mutation in Npps in a mouse model of ossification of the
posterior longitudinal ligament of the spine. Nat Genet 1998,
19:271-273.
38. Hosoda Y, Yoshimura Y, Higaki S: A new breed of mouse
showing multiple osteochondral lesions – twy mouse.
Ryumachi 1981, 21 Suppl:157-164.
39. Li Q, Guo H, Chou DW, Berndt A, Sundberg JP, Uitto J: Mutant
Enpp1(asj) mice as a model for generalized arterial
calcification of infancy. Dis Model Mech 2013, 6:1227-1235.
40. Li Q, Pratt CH, Dionne LA, Fairfield H, Karst SY, Sundberg JP,
Uitto J: Spontaneous asj-2J mutant mouse as a model for
generalized arterial calcification of infancy: a large deletion/
insertion mutation in the Enpp1 gene. PLoS One 2014,
9:e113542.
41. Johnson K, Polewski M, van Etten D, Terkeltaub R:
Chondrogenesis mediated by PPi depletion promotes
spontaneous aortic calcification in NPP1S/S mice. Arterioscler
Thromb Vasc Biol 2005, 25:686-691.
42. Mackenzie NCW, Zhu D, Milne EM, van ’t Hof R, Martin A,
Quarles DL, Milla´n JL, Farquharson C, MacRae VE: Altered bone
development and an increase in FGF-23 expression in
Enpp1S/S mice. PLoS One 2012, 7:e32177.
43.

Hajjawi MOR, MacRae VE, Huesa C, Boyde A, Milla´n JL, Arnett TR,
Orriss IR: Mineralisation of collagen rich soft tissues and
osteocyte lacunae in Enpp1(S/S) mice. Bone 2014, 69C:
139-147.
This study demonstrated for the first time that ENPP1 is expressed both in
osteocytes and osteoclasts and further characterizes the ENPP1/
mouse phenotype.
44. Huesa C, Zhu D, Glover JD, Ferron M, Karsenty G, Milne EM,
Millan JL, Ahmed SF, Farquharson C, Morton NM et al.:
Deficiency of the bone mineralization inhibitor NPP1 protectsCurrent Opinion in Pharmacology 2016, 28:14–23
22 Musculoskeletalagainst obesity and diabetes. Dis Model Mech 2014, 7:
1341-1350.
45. Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G,
Strom TM: Loss-of-function ENPP1 mutations cause both
generalized arterial calcification of infancy and autosomal-
recessive hypophosphatemic rickets. Am J Hum Genet 2010,
86:267-272.
46. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D,
Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J et al.:
Autosomal-recessive hypophosphatemic rickets is
associated with an inactivation mutation in the ENPP1 gene.
Am J Hum Genet 2010, 86:273-278.
47. Sholler GF, Yu JS, Bale PM, Hawker RE, Celermajer JM,
Kozlowski K: Generalized arterial calcification of infancy: three
case reports, including spontaneous regression with long-
term survival. J Pediatr 1984, 105:257-260.
48. Nitschke Y, Baujat G, Botschen U, Wittkampf T, du Moulin M,
Stella J, Le Merrer M, Guest G, Lambot K, Tazarourte-
Pinturier MF et al.: Generalized arterial calcification of
infancy and pseudoxanthoma elasticum can be caused by
mutations in either ENPP1 or ABCC6. Am J Hum Genet 2012,
90:25-39.
49. Nitschke Y, Rutsch F: Generalized arterial calcification of
infancy and pseudoxanthoma elasticum: two sides of the
same coin. Front Genet 2012, 3:302.
50.

Albright RA, Stabach P, Cao W, Kavanagh D, Mullen I,
Braddock AA, Covo MS, Tehan M, Yang G, Cheng Z et al.: ENPP1-
Fc prevents mortality and vascular calcifications in rodent
model of generalized arterial calcification of infancy. Nat
Commun 2015, 6:10006.
This is the first report to demonstrate the efficacy of exogenous recom-
binant ENPP1 to treat GACI.
51. Von Magnus-Levy A: Ueber ungewo¨hnliche Verkalkung der
Arterien. Dtsch Med Wochenschr 1914, 40:1305-1309.
52. St. Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F,
Carlson-Donohoe H, Lederman RJ, Chen MY, Yang D et al.: NT5E
mutations and arterial calcifications. N Engl J Med 2011,
364:432-442.
53. Zhang Z, He JW, Fu WZ, Zhang CQ, Zhang ZL: Calcification of
joints and arteries: second report with novel NT5E
mutations and expansion of the phenotype. J Hum Genet
2015, 60:561-564.
54. Yegutkin GG: Nucleotide-and nucleoside-converting
ectoenzymes: important modulators of purinergic signalling
cascade. BBA Mol Cell Res 2008, 1783:673-694.
55. Markello TC, Pak LK, St. Hilaire C, Dorward H, Ziegler SG,
Chen MY, Chaganti K, Nussbaum RL, Boehm M, Gahl WA:
Vascular pathology of medial arterial calcifications in NT5E
deficiency: implications for the role of adenosine in
pseudoxanthoma elasticum. Mol Genet Metab 2011, 103:44-50.
56. Nair K, Ramachandran P, Krishnamoorthy KM, Dora S,
Achuthan TJ: Hutchinson–Gilford progeria syndrome with
severe calcific aortic valve stenosis and calcific mitral valve. J
Heart Valve Dis 2004, 13:866-869.
57. Salamat M, Dhar PK, Neagu DL, Lyon JB: Aortic calcification in a
patient with Hutchinson–Gilford progeria syndrome. Pediatr
Cardiol 2010, 31:925-926.
58. Hanumanthappa NB, Madhusudan G, Mahimarangaiah J,
Manjunath CN: Hutchinson–Gilford progeria syndrome with
severe calcific aortic valve stenosis. Ann Pediatr Cardiol 2011,
4:204.
59. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L,
Erdos MR, Robbins CM, Moses TY, Berglund P: Recurrent de
novo point mutations in lamin A cause Hutchinson–Gilford
progeria syndrome. Nature 2003, 423:293-298.
60. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J,
Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M et al.:
Lamin A truncation in Hutchinson–Gilford progeria. Science
2003, 300:2055.Current Opinion in Pharmacology 2016, 28:14–23 61. Villa-Bellosta R, Rivera-Torres J, Osorio FG, Acı´n-Pe´rez R,
Enriquez JA, Lo´pez-Otı´n C, Andre´s V: Defective extracellular
pyrophosphate metabolism promotes vascular calcification in
a mouse model of Hutchinson–Gilford progeria syndrome that
is ameliorated on pyrophosphate treatment. Circulation 2013,
127:2442-2451.
62. Keutel J, Jorgensen G, Gabriel P: A new autosomal-recessive
hereditary syndrome. Multiple peripheral pulmonary stenosis,
brachytelephalangia, inner-ear deafness, ossification or
calcification of cartilages. Dtsch Med Wochenschr 1971,
96:1676-1681 passim.
63. Khosroshahi HE, Uluoglu O, Olgunturk R, Basaklar C: Keutel
syndrome: a report of four cases. Eur J Pediatr 1989, 149:188-191.
64. Ziereisen F, De Munter C, Perlmutter N: The Keutel syndrome.
Report of a case and review of the literature. Pediatr Radiol
1993, 23:314-315.
65. Meier M, Weng LP, Alexandrakis E, Ruschoff J, Goeckenjan G:
Tracheobronchial stenosis in Keutel syndrome. Eur Respir J
2001, 17:566-569.
66. Hur DJ, Raymond GV, Kahler SG, Riegert-Johnson DL, Cohen BA,
Boyadjiev SA: A novel MGP mutation in a consanguineous
family: review of the clinical and molecular characteristics of
Keutel syndrome. Am J Med Genet A 2005, 135:36-40.
67. Cranenburg EC, Vans-Z KY, Bonafe L, Mittaz Crettol L,
Rodiger LA, Dikkers FG, Vane AJ, Superti-Furga A, Alexandrakis E,
Vermeer C et al.: Circulating matrix gamma-carboxyglutamate
protein (MGP) species are refractory to vitamin K treatment in
a new case of Keutel syndrome. J Thromb Haemost 2011,
9:1225-1235.
68. Sun LF, Chen X: Tracheobronchial stenosis in Keutel
syndrome. Indian Pediatr 2012, 49:759.
69. Khosroshahi HE, Sahin SC, Akyuz Y, Ede H: Long term follow-up
of four patients with Keutel syndrome. Am J Med Genet A 2014,
164A:2849-2856.
70. Munroe PB, Olgunturk RO, Fryns J-P, Maldergem LV, Ziereisen F,
Yuksel B, Gardiner RM, Chung E: Mutations in the gene
encoding the human matrix Gla protein cause Keutel
syndrome. Nat Genet 1999, 21:142-144.
71. Bayramoglu A, Saritemur M, Tasdemir S, Omeroglu M, Erdem HB,
Sahin I: A rare cause of dyspnea in emergency medicine:
Keutel syndrome. Am J Emerg Med 2015.
72. Weaver KN, El Hallek M, Hopkin RJ, Sund KL, Henrickson M, Del
Gaudio D, Yuksel A, Acar GO, Bober MB, Kim J et al.: Keutel
syndrome: report of two novel MGP mutations and discussion
of clinical overlap with arylsulfatase E deficiency and relapsing
polychondritis. Am J Med Genet A 2014, 164A:1062-1068.
73. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR,
Karsenty G: Spontaneous calcification of arteries and cartilage
in mice lacking matrix GLA protein. Nature 1997, 386:78-81.
74. Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM,
Shanahan CM, Vermeer C, Weissberg PL, Proudfoot D: Post-
translational modifications regulate matrix Gla protein
function: importance for inhibition of vascular smooth muscle
cell calcification. J Thromb Haemost 2007, 5:2503-2511.
75.

Malhotra R, Burke MF, Martyn T, Shakartzi HR, Thayer TE,
O’Rourke C, Li P, Derwall M, Spagnolli E, Kolodziej SA et al.:
Inhibition of bone morphogenetic protein signal transduction
prevents the medial vascular calcification associated with
matrix Gla protein deficiency. PLoS One 2015, 10:e0117098.
This study demonstrates that inhibiting BMP signalling decreases vas-
cular calcification in MGP/ mice and that some of the features of MGP/
 are dependent on BMP signalling.
76. Kaplan FS, Chakkalakal SA, Shore EM: Fibrodysplasia
ossificans progressiva: mechanisms and models of skeletal
metamorphosis. Dis Model Mech 2012, 5:756-762.
77. Brampton C, Aherrahrou Z, Chen LH, Martin L, Bergen AA,
Gorgels TG, Erdmann J, Schunkert H, Szabo Z, Varadi A et al.:
The level of hepatic ABCC6 expression determines the
severity of calcification after cardiac injury. Am J Pathol 2014,
184:159-170.www.sciencedirect.com
Rare connective tissue calcifying diseases Rashdan et al. 2378. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho T-J,
Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M et al.: A
recurrent mutation in the BMP type I receptor ACVR1 causes
inherited and sporadic fibrodysplasia ossificans progressiva.
Nat Genet 2006, 38:525-527.
79. Song G-A, Kim H-J, Woo K-M, Baek J-H, Kim G-S, Choi J-Y,
Ryoo H-M: Molecular consequences of the ACVR1R206H
mutation of fibrodysplasia ossificans progressiva. J Biol Chem
2010, 285:22542-22553.
80. van Dinther M, Visser N, de Gorter DJ, Doorn J, Goumans MJ, de
Boer J, ten Dijke P: ALK2 R206H mutation linked to
fibrodysplasia ossificans progressiva confers constitutive
activity to the BMP type I receptor and sensitizes
mesenchymal cells to BMP-induced osteoblast differentiation
and bone formation. J Bone Miner Res 2010, 25:1208-1215.
81. Groppe JC, Wu J, Shore EM, Kaplan FS: In vitro analyses of the
dysregulated R206H ALK2 kinase–FKBP12 interaction
associated with heterotopic ossification in FOP. Cells Tissues
Organs 2011, 194:291-295.
82. Chakkalakal SA, Zhang D, Culbert AL, Convente MR, Caron RJ,
Wright AC, Maidment AD, Kaplan FS, Shore EM: An Acvr1 R206H
knock-in mouse has fibrodysplasia ossificans progressiva. J
Bone Miner Res 2012, 27:1746-1756.
83. Lounev VY, Ramachandran R, Wosczyna MN, Yamamoto M,
Maidment AD, Shore EM, Glaser DL, Goldhamer DJ, Kaplan FS:
Identification of progenitor cells that contribute to heterotopic
skeletogenesis. J Bone Joint Surg 2009, 91:652-663.
84. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR:
Conversion of vascular endothelial cells into multipotent
stem-like cells. Nat med 2010, 16:1400-1406.
85. Wosczyna MN, Biswas AA, Cogswell CA, Goldhamer DJ:
Multipotent progenitors resident in the skeletal muscle
interstitium exhibit robust BMP-dependent osteogenic
activity and mediate heterotopic ossification. J Bone Miner Res
2012, 27:1004-1017.
86. Gobbi G: Orphanet: Celiac Disease, Epilepsy and Cerebral
Calcification Syndrome. 2012.
87. Gobbi G: Coeliac disease, epilepsy and cerebral calcifications.
Brain Dev 2005, 27:189-200.
88. Arroyo HA, De Rosa S, Ruggieri V, de Davila MT, Fejerman N:
Epilepsy, occipital calcifications, and oligosymptomatic
celiac disease in childhood. J Child Neurol 2002, 17:800-806.
89. Calvani M Jr, Parisi P, Guaitolini C, Parisi G, Paolone G: Latent
coeliac disease in a child with epilepsy, cerebral
calcifications, drug-induced systemic lupus erythematosus
and intestinal folic acid malabsorption associated with
impairment of folic acid transport across the blood–brain
barrier. Eur J Pediatr 2001, 160:288-292.
90. Johnson AM, Dale RC, Wienholt L, Hadjivassiliou M,
Aeschlimann D, Lawson JA: Coeliac disease, epilepsy, andwww.sciencedirect.com cerebral calcifications: association with TG6 autoantibodies.
Dev Med Child Neurol 2013, 55:90-93.
91. Sobrido MJ, Coppola G, Oliveira J, Hopfer S, Geschwind DH:
Primary Familial Brain Calcification. 2013.
92. Wang C, Li Y, Shi L, Ren J, Patti M, Wang T, de Oliveira JR,
Sobrido MJ, Quintans B, Baquero M et al.: Mutations in SLC20A2
link familial idiopathic basal ganglia calcification with
phosphate homeostasis. Nat Genet 2012, 44:254-256.
93. Schottlaender L, Mencacci N, Koepp M, Hanna M, Hardy J,
Lees A, Houlden H: Interesting Clinical Features Associated with
Mutations in the SLC20A2 Gene. 2012.
94. Hsu SC, Sears RL, Lemos RR, Quintans B, Huang A, Spiteri E,
Nevarez L, Mamah C, Zatz M, Pierce KD et al.: Mutations in
SLC20A2 are a major cause of familial idiopathic basal ganglia
calcification. Neurogenetics 2013, 14:11-22.
95. Lemos RR, Oliveira MF, Oliveira JRM: Reporting a new mutation
at the SLC20A2 gene in familial idiopathic basal ganglia
calcification. Eur J Neurol 2013, 20:e43-e44.
96. Zhang Y, Guo X, Wu A: Association between a novel mutation in
SLC20A2 and familial idiopathic basal ganglia calcification.
PLoS One 2013, 8:e57060.
97. Jensen N, Schrøder HD, Hejbøl EK, Fu¨chtbauer E-M, de
Oliveira JRM, Pedersen L: Loss of function of Slc20a2
associated with familial idiopathic basal ganglia calcification
in humans causes brain calcifications in mice. J Mol Neurosci
2013, 51:994-999.
98. Nicolas G, Pottier C, Maltete D, Coutant S, Rovelet-Lecrux A,
Legallic S, Rousseau S, Vaschalde Y, Guyant-Marechal L,
Augustin J et al.: Mutation of the PDGFRB gene as a cause of
idiopathic basal ganglia calcification. Neurology 2013, 80:181-
187.
99. Kakita A, Suzuki A, Nishiwaki K, Ono Y, Kotake M, Ariyoshi Y,
Miura Y, Oiso Y: Stimulation of Na-dependent phosphate
transport by platelet-derived growth factor in rat aortic
smooth muscle cells. Atherosclerosis 2004, 174:17-24.
100. Villa-Bellosta R, Levi M, Sorribas V: Vascular smooth muscle cell
calcification and SLC20 inorganic phosphate transporters:
effects of PDGF, TNF-a, and Pi. Pflug Arch Eur J Phy 2009,
458:1151-1161.
101.

Tsang HG, Rashdan NA, Whitelaw CBA, Corcoran BM, Summers
KM1, MacRae VE: Large animal models of cardiovascular
disease. Cell Biochem Funct 2016 http://dx.doi.org/10.1002/
cbf.3173.
This paper provides a current indepth review of large animal models
relevant to cardiovascular disease.
102.

Hsu PD, Lander ES, Zhang F: Development and applications of
CRISPR-Cas9 for genome engineering. Cell 2014, 157:
1262-1278.
This review describes the development and applications of Cas9 for a
variety of research and translational applications.Current Opinion in Pharmacology 2016, 28:14–23
